CytomX CTMX 深 沪
等待开盘 10-06 09:30:00 美东时间
2.58
+0.020
+0.78%
华盛通- 最 高3.885
- 今 开2.55
- 成交量 175.86万股
- 最 低 2.48
- 昨 收 2.56
- 总市值 1.69亿
- 52周最高 8.21
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.48
- 委 比 -72.14%
- 总股本 6539.84万
- 历史最高 35.00
- 量 比 0.62
- 振 幅 54.88%
- 历史最低 0.40
- 每 手 1
- 风险率 0.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Market-Moving News for March 16th
NBIS: 17% | Nebius Announced 5-Year $12B AI Infrastructure Agreement With Meta To Provide Dedicated Capacity Across Multiple Locations Using NVIDIA Vera Rubin Platform Starting Early 2027 CTMX: 70%
03-16 19:30
Earnings Scheduled For March 16, 2026
Companies Reporting Before The Bell • CytomX Therapeutics (NASDAQ:CTMX) is expe...
03-16 19:11
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
2025-11-06 19:12
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
CytomX Therapeutics CEO Sean McCarthy will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025. The company, focused on developing localized biologics for cancer treatment, will also offer one-on-one meetings with investors. Key products include CX-2051 and CX-801, aiming to target cancer cells more effectively.
2025-05-29 12:00
Why Gap Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Shares of The Gap, Inc. (NYSE:GAP) rose sharply in today's pre-market trading a...
2025-03-07 20:19
HC Wainwright & Co. Reiterates Neutral on CytomX Therapeutics
HC Wainwright & Co. analyst Mitchell Kapoor reiterates CytomX Therapeutics (NASDAQ:CTMX) with a Neutral.
2024-09-13 18:34
HC Wainwright & Co. Reiterates Neutral on CytomX Therapeutics
HC Wainwright & Co. analyst Mitchell Kapoor reiterates CytomX Therapeutics (NASDAQ:CTMX) with a Neutral.
2024-08-22 19:31
